FDA’s institutional review board committee
FDA Assistant Commissioner for Science Linda Tollefson becomes the new chair of FDA's Institutional Review Board's Research Involving Human Subjects Committee July 1. She replaces former RIHSC chair and FDA's Office of Orphan Products Development Deputy Director John McCormick, who plans to retire from the agency soon. McCormick was RIHSC chairman for three and a half years and served as deputy director of OOPD for eight years of his 16 years with the office. His successor at OOPD has not yet been determined, FDA says...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”